Articles

Preparing to launch personalized medicine

Air Force longitudinal study aims to prepare healthcare providers for a world rife with personal genomic information
Written byJim Cirigliano
| 3 min read

TRAVIS AIR FORCE BASE, Calif.—TheUnited States Air Force has brought aboard the Coriell Institute forMedical Research to enroll 2,000 active-duty healthcare providers aspart of a broad-based program designed to prepare for and enable theuse of personal genomic information in clinical practice.

The partnership with the CoriellInstitute is part of the Air Force's PC2-Z longitudinal study,which aims to advance and eventually implement genome-informedpersonalized medicine.

Better technology and less expensivescreening methods provide the impetus for the Air Force MedicalService (AFMS), as well as other medical providers, to begin tounderstand the ramifications of personalized genomic informationbecoming readily available.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Researcher examining a multiwell plate alongside cell culture dishes in a laboratory.
Explore how direct cell lysis can reduce sample preparation steps and support efficient gene expression analysis by RT-qPCR.
Abstract rainbow-colored beams of light spreading across a dark background.
Compare fluorochromes based on resolution, spillover, antigen expression, and other factors that can affect panel performance.
Illustration of multiple glowing blue and purple spherical cells against a dark blue background.
As researchers embrace more complex cellular models, high-content analysis brings new opportunities and challenges to drug discovery.